WANY
ATNM icon

Wealthspire Advisors (New York)’s Actinium Pharmaceuticals ATNM Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,348
Closed -$127K – 541
2021
Q3 		$127K Buy
+14,348
New +$99.8K ﹤0.01% 562

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wealthspire Advisors (New York)'s ATNM Position: Q4 2021 in Review

Wealthspire Advisors (New York) sold out of Actinium Pharmaceuticals (ATNM) in Q4 2021, closing a stake of 14,348 shares — an estimated $127K sold.

Wealthspire Advisors (New York) first reported a position in ATNM in Q3 2021 and held it in 1 quarter. The position peaked at $127K in Q3 2021. 42 funds tracked by Wall St. Rank hold ATNM as of Q4 2021.

  • Wealthspire Advisors (New York) reported no remaining Actinium Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 14,348 Actinium Pharmaceuticals shares in Q4 2021, an estimated $127K.
  • Wealthspire Advisors (New York) first reported a position in Actinium Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Actinium Pharmaceuticals position peaked at $127K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2021.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.